Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashley McKhann

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Epidemics|March 18, 2019
Efficient vaccination strategies for epidemic control using network informationYingrui Yang, Ashley McKhann, Sixing Chen, et al.
AIDS Research and Human Retroviruses|June 11, 2019
Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral TherapyAdriana Tovar Salazar, Ashley McKhann, Huichao Chen, et al.
AIDS (London, England)|June 4, 2019
Soluble suppression of tumorigenicity 2 levels are not predictive of non-AIDS events during antiretroviral therapy-mediated viral suppressionAlexis Kay, Carlee Moser, Ashley McKhann, et al.
AIDS (London, England)|August 9, 2021
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapyThomas A Premeaux, Carlee B Moser, Ashley McKhann, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 25, 2021
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297)Douglas Shaffer, Johnstone Kumwenda, Huichao Chen, et al.
Open Forum Infectious Diseases|February 11, 2022
Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral TherapyThomas A Premeaux, Carlee B Moser, Ashley McKhann, et al.
AIDS (London, England)|April 10, 2020
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical eventsSara Gianella, Carlee Moser, Andrej Vitomirov, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 13, 2025
The Effect of Low Dose Methotrexate on Arterial Inflammation in Persons Living with Human Immunodeficiency Virus. A double-blind randomized placebo-controlled pilot trialAhmed Tawakol, Heather Ribaudo, Ashley McKhann, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Open Forum Infectious Diseases|January 5, 2026
Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB TrialMoises A Huaman, Manuel G Feria, Michelle A Kendall, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Epidemics|March 18, 2019
Efficient vaccination strategies for epidemic control using network informationYingrui Yang, Ashley McKhann, Sixing Chen, et al.
AIDS Research and Human Retroviruses|June 11, 2019
Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral TherapyAdriana Tovar Salazar, Ashley McKhann, Huichao Chen, et al.
AIDS (London, England)|June 4, 2019
Soluble suppression of tumorigenicity 2 levels are not predictive of non-AIDS events during antiretroviral therapy-mediated viral suppressionAlexis Kay, Carlee Moser, Ashley McKhann, et al.
AIDS (London, England)|August 9, 2021
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapyThomas A Premeaux, Carlee B Moser, Ashley McKhann, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 25, 2021
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297)Douglas Shaffer, Johnstone Kumwenda, Huichao Chen, et al.
Open Forum Infectious Diseases|February 11, 2022
Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral TherapyThomas A Premeaux, Carlee B Moser, Ashley McKhann, et al.
AIDS (London, England)|April 10, 2020
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical eventsSara Gianella, Carlee Moser, Andrej Vitomirov, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 13, 2025
The Effect of Low Dose Methotrexate on Arterial Inflammation in Persons Living with Human Immunodeficiency Virus. A double-blind randomized placebo-controlled pilot trialAhmed Tawakol, Heather Ribaudo, Ashley McKhann, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Open Forum Infectious Diseases|January 5, 2026
Monocyte Activation in People With HIV and Tuberculosis Coinfection and Effect of Tuberculosis Preventive Therapy: An Analysis of the ACTG A5279/BRIEF TB TrialMoises A Huaman, Manuel G Feria, Michelle A Kendall, et al.
Pageof 2